Product Description: Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC)[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Zhu C, et al. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Front Immunol. 2020 Aug 14;11:1771.
CAS Number: 1461640-62-9
Molecular Weight: N/A
Compound Purity: 98.44
Research Area: cancer
Solubility: 10 mM in DMSO
Target: CD38